Highlights Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
0.1486 ^USD	-3.32%		+0.41%	-12.38%

04-03	Sector Update: Health Care Stocks Softer Late Afternoon	MT
04-03	Sector Update: Health Care	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Softer Late Afternoon	04-03	MT
Sector Update: Health Care	04-03	MT
Top Midday Gainers	04-03	MT
TuHURA Biosciences, Inc. entered into a definitive agreement to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.	04-02	CI
TuHURA Biosciences, Inc. agreed to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.	04-02	CI
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab	03-27	CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-14	CI
Kintara Therapeutics, Inc. Announces Initiation of Rem-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer	02-12	CI
Kintara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-13	CI
Kintara Therapeutics Announces Preliminary Topline Results from GBM AGile Study	23-10-31	CI
Kintara Therapeutics, Inc. Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting	23-09-25	CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-18	CI
Bank Stocks Lift Exchange-Traded Funds, Equity Futures Pre-Bell Thursday After Stress Test Results	23-06-29	MT
Kintara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11	CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-14	CI
Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma	22-12-15	CI
Kintara Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price Requirement	22-11-30	MT
Kintara Therapeutics Grants Fast Track Designation from FDA for Rem-001 for Cutaneous Metastatic Breast Cancer	22-11-28	CI
Kintara Therapeutics to Effect 1-for-50 Reverse Stock Split; Shares Fall	22-11-11	MT
Earnings Flash (KTRA) KINTARA THERAPEUTICS Posts Q1 Loss $-0.07	22-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Highlights

Filters